pharma · Haemophilia A · Still's Disease, Juvenile Onset
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum is a pharma organization headquartered in Stockholm, JP. Primary therapeutic focus areas include Haemophilia A, Still's Disease, Juvenile Onset, Primary Myelofibrosis, Transplant-associated Throm
Stockholm, JP HQ
2020 Founded
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Stockholm, JP
- Founded
- 2020
- Employees
- 6
- Programs
- 7
- Drugs
- 12
- Patents
- 0
Sobi.PEGCET-201
Phase 2 · other · Transplant-associated Thrombotic Microangiopathy (TA TMA)
Sobi.PEGCET-201 for Transplant-associated Thrombotic Microangiopathy (TA TMA) is a Phase 2 program (other) at Swedish Orphan Biovitrum AB (publ) with 1 ClinicalTrials.gov record(s).
Internal code Sobi.PEGCET-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Swedish Orphan Biovitrum AB (publ)
- Phase
- Phase 2
- Modality
- other
- Indication
- Transplant-associated Thrombotic Microangiopathy (TA TMA)
- Status
- active
- Trials
- 1